

Cover Story
Clinical
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- NIH Director Jay Bhattacharya launches a podcast
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- “Forward funding” NIH budget plan would make competing for grants much harder
- Optimizing dosing of expensive and toxic oncology drugs: Making America healthier